Ricardo Ferreira

Ricardo Ferreira

Auto-generated profile, based on publicly available information

Ricardo Ferreira

μRoboptics, Lisbon, Portugal

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2025 in Journal of Breath Research
Verified
Journal Article
Open access
PDF file
JPJorrit van Poelgeest
Jorrit van Poelgeest
SKShahriyar Shahbazi Khamas
Shahriyar Shahbazi Khamas
AHAhmed Hallawa
Ahmed Hallawa
CDCristian Carlos D'ALessandro
Cristian Carlos D'ALessandro
RFRicardo Ferreira
Ricardo Ferreira
PBPaul Brinkman
Paul Brinkman
Rationale: Chronic obstructive pulmonary disease (COPD) exacerbations significantly contribute to disease progression, hospitalizations, and decreased quality of life. Early detection of exacerbations through non-invasive methods, such as exhaled volatile organic compounds (VOCs), could enable timely interventions. This study aimed to identify and validate candidate VOC biomarkers that are associated with exacerbations and stable phases of COPD, and could contribute to the development of a breath-based monitoring device. Methods: A systematic review was conducted to identify VOCs associated with COPD and exacerbations. VOCs were selected as candidate biomarkers if they were reported in at least two studies by different research groups. These VOCs were then validated using longitudinal exhaled breath data from the TEXACOLD study, where exhaled breath samples were collected at baseline, during exacerbation, and at follow-up in 14 COPD patients. Sparse Partial Least Squares-Discriminant Analysis (sPLS-DA) was applied to differentiate between samples collected during exacerbation and those at stable phases. Diagnostic accuracy was assessed using Receiver Operating Characteristic (ROC) curves. Results: The systematic review identified nine candidate VOCs. Three were excluded from validation because their dataset overlapped with one used in one of the included review studies. Validation confirmed the discriminatory power of a composite model of these six VOCs, achieving an area under the ROC curve of 0.98, a diagnostic accuracy of 94.3% and a sensitivity of 0.97 and a specificity of 0.93. Conclusion: This study demonstrates that exhaled VOCs can differentiate between exacerbations and stable phases in COPD patients. The validated biomarkers hold promise for future clinical applications, particularly in the development of a non-invasive, breath-based monitoring device for early detection and management of COPD exacerbations, potentially reducing hospitalizations and improving patient outcomes.